Rochester News

 

URMC Co-Leading Study of Parkinson's Drug

URMC Co-Leading Study of Parkinson's Drug

Rochester, NY -- The University of Rochester and Northwestern University are co-leading a new Phase 3 clinical trial of a potential new treatment for Parkinson's disease.

The evaluation of the drug, called isradipine, is being funded with a $23 million grant from the National Institutes of Health.

URMC neurologist Kevin Biglan says the drug has been demonstrated to be safe and tolerable in Parkinson’s patients. He says the new study will determine whether it can be an effective tool in slowing the progression of the disease and could, thereby, complement existing treatments and improve the quality of life for patients.

 

 

More Articles